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HPV16 E7 oncoprotein expression in K14E7 transgenic mice induces cervical cancer after 6 months of
treatment with the co-carcinogen 17b-estradiol. In untreated mice, E7 also induces skin tumors late in
life albeit at low penetrance. These ﬁndings indicate that E7 alters cellular functions in cervix and skin
so as to predispose these organs to tumorigenesis. Using microarrays, we determined the global genes
expression proﬁle in cervical and skin tissue of young adult K14E7 transgenic mice without estrogen
treatment. In these tissues, the E7 oncoprotein altered the transcriptional pattern of genes involved in
several biological processes including signal transduction, transport, metabolic process, cell adhesion,
apoptosis, cell differentiation, immune response and inﬂammatory response. Among the E7-dysregulated
genes were ones not previously known to be involved in cervical neoplasia including DMBT1, GLI1 and
17bHSD2 in cervix, as well as MMP2, 12, 14, 19 and 27 in skin.
& 2012 Elsevier Inc. All rights reserved.Introduction
‘‘High risk’’ human papillomaviruses (HPVs) genotypes of
greatest frequency, HPV16 and HPV18, are the causative agents
of the majority of cervical and other anogenital cancers and a
subset of head and neck cancers (Munoz et al., 2003; zur Hausen,
1996). The transforming potential of oncogenic HPVs is closely
linked to the expression of the viral E6 and E7 genes, which
encode oncoproteins best known for their ability to inactivate the
cellular tumor suppressors p53 and RB, respectively (McLaughlin-
Drubin and Munger, 2009). These viral oncoproteins also are
known to bind to and modify the activity of many other cellular
proteins, thereby compromising multiple processes involved in
cellular homeostasis and transformation (McLaughlin-Drubin and
Mu¨nger, 2009; Munger et al., 2001).
Extensive studies on the oncogenic properties of HPV16 E6 and
E7 have been carried out in vivo using genetically engineered
HPV16 transgenic mice, in which expression of E6 and/or E7 werell rights reserved.targeted to the basal cells of the squamous epithelium under the
control of the human keratin 14 (K14) transcriptional promoter
(Herber et al., 1996b). E6 and E7 oncoproteins, together, induced
cancers in multiple epithelial tissues in which they were
expressed, including squamous cell carcinoma of the skin
(Herber et al., 1996a; Song et al., 1999), the cervix (Arbeit et al.,
1994; Riley et al., 2003), the head/neck region (Strati et al., 2006)
and the anus (Stelzer et al., 2010; Thomas et al., 2011). Impor-
tantly, in the cervix, head/neck and the anus, three sites in which
HPV16 causes cancer in humans, E7 was clearly the more potent
viral oncogene (Shai et al., 2007; Strati et al., 2006; Thomas et al.,
2011).
Based on this knowledge, we set out to deﬁne the global
changes in the expression of cellular genes caused speciﬁcally by
E7. We used high-density oligonucleotide microarrays to compare
the expression proﬁle in the cervix and skin of K14E7 transgenic
compared to that of nontransgenic mice. We focused our analyses
on young adult mice in which neoplastic progression had yet to
have occurred, thereby attempting to deﬁne acute effects of E7
that might contribute early on to the process of carcinogenesis.
Among the biological processes that we found most affected by
HPV16 E7 in both tissues were signal transduction, transport,
metabolic process, cell adhesion, apoptosis, cell differentiation,
immune response and inﬂammatory response.
Fig. 2. Quantiﬁcation of HPV16 E7 gene expression using real time PCR in skin and
cervical tissue. E7 expression was evaluated in a total of 6 mice from each group.
The data are presented as the fold change in E7 mRNA level normalized to the
GAPDH mRNA (endogenous control). Error bars represent the SD. The difference
between E7 mRNA expression in skin versus cervix was statistically signiﬁcant
(po0.005). The signiﬁcant difference is indicated by an asterisk.
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Characterization of mice for microarray analysis
There have been no prior analyses of the effects of HPV16 E7
on host gene expression in vivo. We therefore used a microarray
based strategy to determine global differences in the cellular gene
expression in cervical and skin tissue of young adult K14E7
transgenic mice compared with that of nontransgenic mice of
the same genetic background. By using young adult mice in which
cancers had yet to arise, we hoped to identify genes regulated by
expression of HPV16 E7 that might play an important role in early
stages of carcinogenesis. For the purpose of this study, female
nontransgenic control FVB/N and K14E7 mice (also on the FVB/N
background) were generated (see Materials and methods section).
Once the mice were 1.5 months old, they were sacriﬁced in the
diestrus phase in order to reduce the variability in the levels of
endogenous hormones that could inﬂuence gene expression.
Biopsies were obtained from cervix to skin of nontransgenic
and K14E7 transgenic mice and total RNA was isolated from
these tissues. Quality and quantity of RNA were determined using
procedures detailed in the Materials and methods section.
The E7 oncoprotein has a greater effect on the transcriptional pattern
in skin than cervix
To identify genes that were upregulated or downregulated by
HPV16 E7 in K14E7 transgenic mice, we analyzed the expression
of 28, 853 genes using Affymetrix gene arrays. All transcripts
signiﬁcantly altered in the K14E7 mice were identiﬁed with a fold
change Z1.5 and r1.5 and p-value r0.05 as the threshold
cutoff. (See list of the differentially expressed genes for both
tissues in GEO ID: GSE36219). We noticed that E7 oncoprotein
had a greater effect on the expression of genes in skin than in
cervix (Fig. 1A). In the cervix, we detected a total of 324
differentially expressed genes; of these, 98 were upregulated
and 226 were downregulated. Interestingly, in skin, we found
1889 differentially expressed genes; of these, 1275 were upregu-
lated and 614 were downregulated (Fig. 1A). Fig. 2B shows a Venn
diagram including the genes with altered expression in the skin
and the cervix. The diagram shows that there were 55 genes
with differential expression overlapping in both tissues (seeFig. 1. Global gene expression proﬁle from cervical and skin tissue of K14E7 transgenic
mice and FvB nontransgenic mice samples. (A) It was found that 98 genes were upregula
upregulated and 614 were downregulated in skin. (B) Relatedness of the genes altered in
genes mutually in both tissues. Values were obtained with Z1.5 and r1.5 fold chaSupplementary Table 1). Within this group, there were 8 genes
upregulated (bold in red) or downregulated (bold in green)
coordinately in both tissues. Some of these 8 genes are transcrip-
tional targets of the RB-E2F signaling pathway; among these,
MCM6, CYCLIN E and ATAD2 showed increased expression in both
tissues. However, there were also changes in expression in other
transcriptional target genes of the RB-E2F pathway that did not
overlap in both tissues.
E7 transgene expression is higher in skin than cervix
One explanation for the differences in gene expression
between skin and cervix from K14E7 transgenic mice might be
the difference in expression of the E7 oncoprotein in those tissues.
To determine transgene mRNA expression, we performed real
time PCR using PCR primers amplifying full-length E7. When both
tissues were compared in the diestrus phase, we found that the
expression of E7 mRNA was threefold higher in skin in relation
to cervix. This result can partially explain the greater degree ofmice. Differentially expressed genes were identiﬁed by comparison between K14E7
ted and 226 genes were downregulated in the cervix. In contrast, 1275 genes were
their expression in the skin versus the cervix. n8 represents up- or downregulated
nge and p-value r0.05 as the threshold cutoff.
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other implications in this regard will be discussed later.Differentially expressed genes related pathways
We used Genecodis 2.0 software to interrogate Gene Ontology
categories and thereby identify biological processes altered by E7
and the number of genes affected in each Gene Ontology (GO)
category (Fig. 3 and Supplementary Table 2). These results show
that despite there being a low number of genes overlapping in
their altered expression in the two tissues, most biological
processes affected by E7 were seen affected in both tissues. In
cervix, the biological processes with greatest number of altered
genes were signal transduction, transport, metabolic process,
oxidation-reduction process, apoptosis, inﬂammatory response
and cell cycle. These categories contain a broad variety of genes,
including those encoding interleukins, cyclins, polymerases as
well as the minichromosome maintenance family (MCM) related
to initiation and elongation of replication forks, which were
upregulated in both tissues. On the other hand, the most highly
populated GO categories in skin were signal transduction,Fig. 3. Gene ontology-based biological process pathways altered in skin and cervix from
early carcinogenesis, we imported a list of signiﬁcant up- and downregulated genes for
categories with greatest number of altered genes in both tissues.
Fig. 4. Real time PCR validation of selected genes differentially expressed in cervical
evaluated in a total of 6 mice from each group (transgenic and controls). The data a
(endogenous control). Error bars represent the SD. The table compares fold change difregulation of transcription, transport, metabolic process, multi-
cellular organismal development, oxidation-reduction process,
cell adhesion, apoptosis, proteolysis, phosphorylation, cell differ-
entiation, immune response and inﬂammatory response. Inter-
estingly, we found expression changes in genes previously
reported in cervical cancer including CYCLIN D, PCNA, and
MMP12 (Bae et al., 2001; Long et al., 2006; Vazquez-Ortiz et al.,
2005), as well as in genes that have not been reported in the
literature and might represent early markers of cell transforma-
tion, such as increased mRNA levels for GLI1, SERPINE2, and MIA2
in cervix.Validation of microarray results by real time PCR
To validate the microarray results in cervix, real time PCR was
performed on cDNA from the cervix of K14E7 and nontransgenic
mice (6 mice per genotype) for 10 genes related to various
pathways deﬁned above (Fig. 4) that have or have not been
previously connected to cervical neoplasia. These included
4 downregulated genes (DMBT1, SESN3, HSD17B2 AND PPARg)
and 7 upregulated genes (ATAD2, MCM2, MCM3, MCM4, MCM5,K14E7 transgenic mice. To know biological process pathways involved in K14E7
each tissue to Genecodis 2.0 software. This ﬁgure shows the twenty Gene ontology
tissue of K14E7 transgenic and nontransgenic mice. Expression of each gene was
re presented as the fold change in mRNA level normalized to the GAPDH mRNA
ferences in mRNA levels between microarray and real time PCR results.
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real time PCR was performed on cDNA from the skin of K14E7 and
nontransgenic mice for 5 genes found in the microarray analysis
to be upregulated (MCM6, IRF1, MCM4, CASP8 and MMP2)
(Fig. 5). The results in the real time PCR were consistent with
the results of microarray analysis (Figs. 4 and 5).Validation of microarray results by immunohistochemistry
Due to DMBT1’s importance as tumor suppressor in various
types of cancer and given its strong downregulation in our
analyses, we wanted to determine whether the differential mRNA
expression of DMBT1 results in detectable differences in protein
expression. As shown in Fig. 6, there is a signiﬁcant decrease in
DMBT1 expression due to the presence of the E7 oncoprotein in
transgenic mice (Fig. 6B), as compared to nontransgenic mice
(Fig. 6A). Strong staining of DMBT1 in cell cytoplasm and nucleus
was observed in nontransgenic mice (Fig. 6A), whereas weaker
protein expression was detected in cell cytoplasm of K14E7
transgenic mice (Fig. 6B).Fig. 5. Real time PCR validation of selected genes differentially expressed in skin
of K14E7 transgenic and nontransgenic mice. Expression of each gene was
evaluated in a total of 6 mice from each group (transgenic and controls). The
data are presented as the fold change in mRNA level normalized to the GAPDH
mRNA (endogenous control). Error bars represent the SD. The table compares fold
change differences in mRNA levels between microarray and real time PCR results.
Fig. 6. Immunochemistry of DMBT protein in cervical tissue. Strong expression of DMBT
weaker protein expression was detected in cell cytoplasm of K14E7 transgenic mice (B
nontransgenic mice, using a polyclonal antibody against Dmbt1. These experim
40magniﬁcation). BM: basal membrane.Discussion
In HPV-positive human cancers, two viral genes, E6 and E7, are
preferentially expressed owing largely to the frequent integration
of the viral genome into the host DNA (zur Hausen, 2009). In vivo
studies in the context of HPV16 transgenic mice have shown that
E7 is the most potent oncogene in causing cancer in the skin,
cervix and other relevant organs in which HPV-associated cancers
arise in humans (Riley et al., 2003; Strati et al., 2006; Thomas
et al., 2011).
In this study we employed young adult K14E7 mice to evaluate
the expression patterns induced by the E7 oncoprotein in cervical and
skin tissues with the goal of deﬁning changes in the gene expression
that might be crucial to early steps in cancer development.
Surprisingly, our microarray results showed more gene expres-
sion changes in skin compared to cervix tissue. This observation
may be simply reﬂecting the relative abundance of E7 in the two
tissues; levels of E7 mRNA were threefold higher in skin than in
cervix (Fig. 2). This could be explained by the fact that E7 mRNA
expression in the skin epidermis is not limited to the basal layer,
but is expressed in suprabasal layers as a result of the hyperplasia
and hyperkeratosis (Herber et al., 1996b). Another possibility is
that there is greater heterogeneity in the nature of the cervical
tissue. We obtained cervical tissue from female mice staged
cytologically in diestrus in order to minimize the inﬂuence of
estrogen induced proliferation on the gene expression proﬁles.
However, morphological changes such as atrophic uterus have
been observed during this stage (Tan et al., 2003). This could lead
to heterogeneity in relative levels of mRNA amongst different
cervical samples and thereby lead to reduced members of genes
with signiﬁcant increases/decreases on average across the tissue
samples that were combined for these analyses. On the other
hand, we have not employed laser microdissection; the RNA was
extracted from the entire cervix, including the stroma. In spite of
that, we found E2F target genes previously reported to be
deregulated in cervical cancer such as the MCM family genes,
CYCLIN D and CYCLIN E (Ghittoni et al., 2010; Murphy et al.,
2005). So, these results correlate with the presence of E7 in
cervical epithelium. Some mRNAs identiﬁed in this work could
come from the stroma but there is increasing evidence that
microenvironment surrounding the epithelium is important in
cancer development. In this sense, there is a study in which laser
microdissection and microarrays were combined to analyze
epithelium and stroma cells from graded CINs and cervical cancer
(Murphy et al., 2005). The authors suggested that in CIN 2 an1 in cell cytoplasm and nucleus (open arrows) of nontransgenic mice (A), whereas
). Immunochemistry was performed in 1.5-month-old K14E7 mice compared with
ents are representative of three separate experiments (all micrographs at
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epithelial cells and the surrounding stromal ﬁbroblasts and that
each compartment individually induces the expression of angio-
genic factors. Therefore, the study of the entire cervix in 1.5 month
old mice gives information about genes expressed both in the
epithelium and in the stroma that might cooperate during the
transition to late stages of cervical cancer.
On the other hand, despite the low number of genes (55 genes)
altered both in the skin and cervix, most biological processes
affected by E7 were the same in both tissues (Fig. 3). This
indicates that E7 affected common processes, but in different sets
of genes in the two tissues. Consistent with this, many of the
effects of E7 occurred in target genes of the RB-E2F pathway, but
not necessarily the same genes in both tissues. We observed
upregulation in the expression of E2F-responsive genes such as
the Minichromosome Maintenance (MCM) Complex family,
involved in DNA replication, and cell cycle regulators like CYCLIN
E, CYCLIN D and PCNA (Proliferating Cell Nuclear Antigen).
Consistent with gene expression proﬁling of human cervical
cancer (Pyeon et al., 2007) and strongly supporting the hypothesis
that E7 drives the dysregulation of the cell cycle in HPV-
associated cancers. These same genes have been found to be
upregulated by E7 at the protein level (Bae et al., 2001; Ishimi
et al., 2003; Long et al., 2006; Zerfass et al., 1995). Indeed, MCM7
has been deﬁned as an informative biomarker for human cervical
cancer as well as for cervical cancer arising in HPV16 transgenic
mice (Brake et al., 2003). The MCM proteins function in the early
stages of DNA replication acting as helicases to help unwind the
duplex DNA during the novo synthesis (Tachibana et al., 2005).
The E7 oncoprotein abrogates the critical cell cycle checkpoints
and induces expression of S-phase genes through the E2F tran-
scription factor. MCM and CYCLIN E are key proteins expressed
during this aberrant gene transcriptional activation (McLaughlin-
Drubin and Munger, 2009). Another E2F target gene affected was
ATAD2, whose expression is high in several human tumors and
correlates with the clinical outcome of breast cancer patients
(Ciro´ et al., 2009). ATAD2 binds the MYC oncoprotein and
stimulates its transcriptional activity providing one possible link
to oncogenesis (Ciro´ et al., 2009). In our study, we found over-
expression of ATAD2 in K14E7 transgenic mice when compared to
nontransgenic controls and previously was reported that C-MYC
is also overexpressed in our mouse model (Diaz-Chavez et al.,
2008). It is likely that E7 upregulates the expression of ATAD2
through its inactivation of RB, which leads to the activation of the
E2F transcription factors. Therefore, we hypothesize that ATAD2
provides a direct link between E7, E2F and the MYC pathway,
which in turn contributes to the development of cervical cancer. It
is worth mentioning that although many E2F-responding, differ-
entially expressed genes were identiﬁed in our microarray ana-
lysis, we did not detect statistically signiﬁcant increased
expression of p16INK4A (p16 mRNA increased 1.7 fold, but the
p value was 0.273). This is a well known marker of progression of
cervical cancer whose expression results from E7-mediated inac-
tivation of the RB–E2F control mechanism and/or by RB indepen-
dent mechanisms such as transcriptional induction of the KDM6B
histone demethylase by E7, which controls the transcriptional
activation of the p16 promoter (McLaughlin-Drubin et al., 2011).
The low or absent increase in p16 mRNA expression observed in
our analysis can be explained taking into account that we used
young adult mice without apparent lesions and that these
animals might present low estrogen levels. However, previous
studies in K14E7 mice already presenting cervical cancer after six
months of estrogen treatment have reported an increase in p16
protein expression (Brake et al., 2003; Shin et al., 2009) similar to
the patterns observed in human malignant cervical samples (Shai
et al., 2007).Another important signaling pathway in cancer is WNT-b-
CATENIN. The accumulation of cytoplasmic b-CATENIN during
WNT signaling pathway activation leads to its nuclear localization
where it binds to the T-cell factor/lymphoid enhancer factor
(TCF/LEF) family of transcription factors resulting in the activation
of target genes that mediate the ultimate effects of this oncogenic
pathway (Lucero et al., 2010). In mammalian cells, b-CATENIN-
TCF/LEF complexes regulate the expression of several proto-
oncogenes, including C-MYC and CYCLIN D1, as well as other
important genes for growth and tumor progression (Kolligs et al.,
2000; Larue and Delmas, 2006). Recently, it has been demon-
strated that E6 and E7 are involved in b-CATENIN nuclear
accumulation and WNT signaling activation (Bonilla-Delgado
et al., 2012; Rampias et al., 2010). In this study, we observed an
increase in LEF1 expression, suggesting that E7 induces the WNT
signaling pathway not only by b-CATENIN nuclear accumulation,
but also by increased expression of LEF1. We previously reported
that C-MYC, a target gene of b-CATENIN-TCF/LEF complexes, is
overexpressed in our mouse model (Diaz-Chavez et al., 2008). In
addition, in this study, we also observed overexpression of
CYCLIN D1, consistent with the WNT signaling pathway being
acutely activated by E7.
Some genes with function in metabolism also were altered
in their levels of expression, among which is PPARg. This gene
regulates the proliferation, apoptosis and differentiation of var-
ious human cancer cells (Lehrke and Lazar, 2005; Rosen and
Spiegelman, 2001). A previous report by Jung et al., 2005 in
humans, found that there were low expression levels of PPARg
mRNA and protein in cervical carcinoma (Jung et al., 2005).
Interestingly, in this study we found decreased PPARg mRNA
expression in the cervix of K14E7 mice, indicating that E7 may be
driving the downregulation of PPARg seen in cervical carcinoma.
An interesting metabolic gene downregulated in the cervix
of K14E7 mice was 17b-hydroxysteroid dehydrogenase type 2
(17b-HSD2), which catalyzes the conversion of the active form of
estrogen, 17b-estradiol, to an inactive form, estrone (Kitawaki
et al., 2000). Thus, E7, by decreasing the expression of 17b-HSD2
in the cervical epithelium could increase the levels of endogenous
estrogen, which has a co-carcinogenic effect in the cervix of this
transgenic mouse model (Brake and Lambert, 2005).
Another important cellular process affected by HPV16 E7 was
the immune response. Speciﬁcally, the Deleted in Malignant Brain
Tumors (DMBT1) gene was the most downregulated gene in the
cervix of K14E7 mice with mRNA levels sixteen fold lower relative
to nontransgenic mice. This gene, located on human chromosome
10q26.13 encodes for a secreted high-molecular-weight glyco-
protein of the scavenger receptor cysteine-rich (SRCR) super-
family and has been proposed as a candidate tumor suppressor
gene for brain, prostate, lung, esophageal, gastric, colorectal, skin
and breast cancers, given the paucity of DMBT1 mRNA and/or
protein in these cancer types (Du et al., 2011; Helmke et al., 2009;
Mollenhauer et al., 2002, 1997). This gene is expressed predomi-
nantly in epithelial cells and its secreted variants have been
shown to play a role in the defense against bacterial and viral
infections as well as in the regulation of inﬂammatory response
and epithelial and/or stem cell differentiation (Hartshorn et al.,
2003; Rosenstiel et al., 2007; Takito and Al-Awqati, 2004). The
loss of DMBT1 expression in patients with prostate cancer has
recently been ascribed to promoter methylation (Du et al., 2011).
In agreement with the downregulation of DMBT1 observed in our
model, there is a study wherein the authors compared differen-
tially expressed genes in HPV-positive versus HPV-negative
oropharyngeal squamous cell carcinoma using Affymetrix micro-
arrays (Martinez et al., 2007) and interestingly they found that
DMBT1 was notably downregulated in HPV-positive patients; these
results suggest that DMBT1 could be a novel early biomarker in
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gene functions as a tumor suppressor in cervical cancer and if its
decreased expression is due to epigenetic changes as observed in
prostate cancer.
Activation of the innate immune response plays an important
role defending or protecting the host against HR-HPV infection
(Daud et al., 2010). Toll-like receptor 2 (TLR2) and TLR4 constitute
membrane-bound pattern recognition receptors that detect viral-
structural proteins resulting in the production of proinﬂamma-
tory cytokines, thereby inducing inﬂammation (Mansur and
Androphy, 1993). HPV16 interferes with innate immunity by
affecting the expression of TLRs (Stanley, 2006). Recently, it was
reported that TLR4 expression is decreased during cervical cancer
progression (Yu et al., 2010). In this study, we observed down-
regulation of genes involved in the innate antiviral response such
as TLR2 and TLR4. We hypothesize that HPV16 E7 modulates the
expression of innate immunity pathways as a mechanism to
escape host defenses and establish a persistent infection, which
in turn is essential for the development of HPV-associated
neoplasias. Interestingly, the expression of genes as STAT1, STAT2,
STAT3 and STAT4 was found to be increased in K14E7 transgenic
mice skin. These genes belong to the JAK/STAT signaling pathway
that mediates signaling from a long list of membrane receptors
that include interferon, interleukin and growth factor receptors.
This suggests that the JAK/STAT signaling pathway is activated by
E7, at least in the skin, which could lead to pleiotropic effects on
cellular responses to a number of extracellular signals, but, in the
case of the innate immune response may be negated by E7’s
suppression of other components of the innate immunity such as
those already mentioned.
Cell migration, a process in which Matrix Metalloproteinases
(MMPs) play crucial roles, was another process strongly affected
by E7 in our study. Epithelial cells can express MMP12 in skin and
vulvar cancers (Kerkela¨ et al., 2000,, 2002). Increased mRNA and
protein levels of both MMP2 and MMP9 have been detected in
breast, colon, pancreatic and cervical cancers and are associated
with poor prognosis in a cancer type-speciﬁc manner (Bergers
et al., 2000; Radisky and Radisky, 2010; Van Trappen et al., 2002;
Vazquez-Ortiz et al., 2005). We observed overexpression of
MMP2, 12, 14, 19 and 27 in skin from young K14E7 transgenic
mice. These ﬁndings could indicate that even in premalignant
HPV-associated lesions conﬁned to epithelium, overexpression of
MMPs might predispose these lesions to acquire an invasive
phenotype.
Finally, it is important to mention that many genes identiﬁed
in this study may not be regulated by E7 directly and could
represent indirect effects of E7 on cellular processes such as
differentiation and proliferation and the corresponding expansion
of cellular populations upon E7 expression in the skin and cervix.
For example, E7 modiﬁes the expression of many genes by the
inactivation of RB and release of E2F transcription factor (Hwang
et al., 2002). HPV16 E7 associates with and diminishes E2F6-
containing polycomb repressive complexes. E7 also induces or
represses indirectly gene expression through its interaction with
AP1 (Antinore et al., 1996) and with the basic transcriptional
machinery, e.g., TATA box binding protein (TBP) (Maldonado
et al., 2002).Conclusion
In summary, the results reported here represent the ﬁrst
comprehensive transcriptome analysis to assess the conse-
quences of HPV16 E7 oncoprotein on cellular gene expression
in vivo. Our observations suggest that, even at the earliest stages
of carcinogenesis, E7 deregulates multiple processes includingsignal transduction, transport, metabolic process, oxidation-
reduction process, cellular adhesion, apoptosis, proteolysis, cel-
lular differentiation, positive regulation of cell proliferation, ion
transport and immune response that might contribute to devel-
opment of cancer. This study identiﬁes many new potential
biomarkers for HPV related carcinogenesis, and provides a basis
to study the potential role of affected cellular genes.Materials and methods
Mouse breeding, care, genotyping and animal sacriﬁce
K14E7 female mice used in this study were already described
(Herber et al., 1996a; Lambert and Brake, 2005). These mice were
bred and maintained on the inbred FVB/N genetic background.
Mice were housed and treated according to the American Asso-
ciation of Laboratory Animal Care (AALAC). All mice procedures
were performed according to a protocol approved by the Research
Unit for Laboratory Animal Care Committee (UPEAL-CINVESTAV-
IPN, Mexico; NOM-062-ZOO-1999). K14E7 mice were genotyped
as described previously (Herber et al., 1996b). K14E7 hemizygote
and nontransgenic FVB/N control virgin female mice were sacri-
ﬁced by cervical dislocation. Skin (approx. 1 cm2) and cervical
biopsies were immediately stored in RNAlater Solution (Ambion)
at 4 1C overnight. Tissue was recovered from RNAlater solution
with sterile forceps, quickly blotted to remove excess RNAlater
and immediately snap frozen in liquid nitrogen.
Microarray sample processing
Total RNA was extracted from snap frozen tissue using
standard procedures (TRIzol reagent, Invitrogen). Total RNA
collected from six female mice of each genotype (K14E7 and
nontransgenic) was pooled. RNA quantity and quality were
assessed on an Agilent 2100 Bioanalyzer (Agilent Technologies).
Only RNA samples with a RNA Integrity Number greater than
8.0 were further processed for microarray analysis. cDNA synth-
esis, ampliﬁcation, and gene expression proﬁling were performed
according to the manufacturer’s instructions (Affymetrix WT
Sense Target labeling assay Manual). Speciﬁcally, 1 mg of total
RNA was used to generate double-stranded cDNA by reverse
transcription using an oligo(dT) primer containing a T7 RNA
polymerase promoter followed by an in vitro transcription to
obtain cRNA molecules. A Second cDNA synthesis was performed
incorporating dUTP nucleotides to newly generated strand. Then,
cDNA fragmentation was performed using a combination of uracil
DNA glycosylase (UDG) and apurinic/apirymidinic endonuclease 1
(APE1). Following fragmentation, the resulting fragmented DNA
was labeled using terminal deoxynucleotidyl transferase (TdT) in
presence of biotinylated nucleotides. The labeled DNA was added
to a hybridization cocktail and then the sample was injected into
the array, (GeneChip Mouse Gene 1.0 ST Array). Washing and
staining steps were carried out using GeneChip Fluidics Station
450. The probe arrays were scanned using the GeneChips Scanner
3000 7G (Affymetrix, Santa Clara CA).
Analysis array data
Signal intensities from each array were analyzed using Partek
Genomic Suite version 6.4 (Partek, Saint Louis MI). Raw intensity
probe values were normalized using robust multiarray analysis
background correction (RMA). A two way ANOVA was performed
to identify differentially expressed genes. Only genes with statis-
tically signiﬁcant differences in expression levels (po0.05) and a
fold-change Z1.5 and r1.5 were included in the ﬁnal set of
Table 1
List of primer sequences for real time PCR used to validate the microarray.
Gene symbol Forward primer Reverse primer Product size pb
HPRT GTAATGATCAGTCAACGGGG CCAGCAAGCTTGCAACCTTAAC 177
Primer 1 and 4 GGCGGATCCTTTTATGCACCAAAAGAGAACTG CCCGGATCCTACCTGCAGGATCAGCCATG 800
E7 ATGGAGATACACCTACATTGCATGA AATGGGCTCTGTCCGGTTCT 100
Up-regulated genes
CASPASE 8 CCAAAGCGCAGACCACAAG GACAGGGAAGGGCACTTTGA 150
LEF1 CCAGACGGAGGCCTGTACAA CTGCACCACGGGCACTTTAT 150
IRF1 AGCATAGTCCCACTGCAAACAG GCCTCTGCCTTACACCTCAGA 150
MMP2 CTCCCCCGATGCTGATACTG CGCCAAATAAACCGGTCCTT 150
ATAD2 TCTCAGCCGACACCCTCACT GTCCCTGCGGTGCTCATAAA 150
MCM2 GCTCTGGCCCTGTTTGGA GAAGATGGCACGGCTAGACACT 150
MCM3 CTGAACAGGATCGGGAGATCTC CTTGCTGGTCATCCTGGGTAA 150
MCM4 CAGAGCCCACCTGCACAGA GCCTCTCACCCCACTTCTTG 150
MCM5 GAGACCGCGGTGGACAAA CACCGAAGCTGTCGCTGTAG 150
MCM6 CTCTGAATGCCAGGACATCCAT CATTGCATTCATCCACCAGAA 150
Down-regulated genes
DMBT1 ACCTTCAGTCCATGGGCTATTC TCTCGTTGTCAGCCTGTTTGA 150
HSD17B2 ACTGTGGGCCGTGGTTAACA GAAGTTCACGGCCATGCAT 135
SESTRINE 3 GTGCTGCGGAAGGACAAAA CAGGCGACCGGATGTAGAGT 150
PPARG TGCCAGTTTCGATCCGTAGAA CATCAGGGAGGCCAGCAT 150
E. Ibarra Sierra et al. / Virology 433 (2012) 337–345 343differentially expressed genes. The microarray data were depos-
ited to the NCBI GEO database [GEO ID: GSE36219]. To identify
those biological processes altered by E7, we used Genecodis 2.0, a
bioinformatic tool for visualizing expression data in the context of
KEGG-deﬁned biological pathways, again using as the cutoff value
those genes altered in the level of expression byZ1.5.
Quantiﬁcation of mRNA using real time PCR
Isolated RNA from six mice from each of the two genotypes
was puriﬁed and its quality determined by electrophoresis on a
2% agarose gel and visualization of ribosomal RNA by ethidium
bromide staining. RNA was quantiﬁed by spectrophotometric
analysis at 260 nm and 280 nm. cDNA synthesis and PCR ampli-
ﬁcation were done as described previously (Mendoza-Villanueva
et al., 2008; Yalcin, 2004). Each gene-speciﬁc RNA was quantiﬁed
in triplicate by real time PCR and mRNA ratios relative to the
house-keeping gene HPRT were calculated for standardization of
gene expression levels across samples using the Ct method. Real
time quantiﬁcation of the amplimers was achieved using SYBR
Green (SYBR Green PCR Reagents Kit, Applied Biosystems) follow-
ing the manufacturer’s recommendations. Before performing the
real time PCR, reaction optimization was done for each gene-
speciﬁc pair of primers to conﬁrm that 50 nM primer concentra-
tions produce speciﬁc primer ampliﬁcation signal. All primer
sequences and product size are described in Table 1. Changes in
ﬂuorescence were recorded as the temperature was increased
from 65 1C to 95 1C at a rate of 0.2 1C s1 to obtain a DNA melting
curve. The characteristic peak at the melting temperature of the
target product distinguishes it from ampliﬁcation artifacts that
melt at lower temperatures in broader peaks.
Data analysis by the comparative Ct method
The 2DDCt equation was used to determine quantitative
comparison of the ampliﬁcation of the candidate genes
(Table 1). Each gene was analyzed in six biological replicates
and three technical replicates. We used the average DCT from skin
or cervix from non transgenic mice as calibrator for each gene
tested. Data are presented as mean7standard deviation (S.D.).
Statistical evaluation of signiﬁcant differences was performed
using the Student’s t-test. Differences of po0.05 were considered
statistically signiﬁcant.Immunohistochemistry
Cervix samples were ﬁxed in 4% paraformaldehyde, embedded
in parafﬁn, and cut into 5 mm sections. Serial sections were used
for hematoxylin and eosin staining and immunohistochemical
staining for DMBT1. For immunohistochemical stains, sections
were deparafﬁnized in xylenes and rehydrated through a grades
series of ethanol-water solutions. Slides were washed in PBS and
heated in boiling 10 mM sodium citrate for 20 min. Samples were
blocked at ambient temperature by treatment with 10% goat
serum and 1% BSA in phosphate-buffered saline (PBS) by 1 h.
Primary antibody was diluted and applied as follows: 99 ml TBS,
1 mg BSA and 1 ml anti-DMBT1 (Santa Cruz Biotechnology, Inc.)
overnight at 4 1C. Endogenous peroxidase activity was quenched
by treatment with 1 drop of PolyDetector (Bio SB Kit). After
washes in PBS two times, biotinylated secondary antibody and
streptavidin-peroxidase conjugate was applied according to the
Bio SB kit’s instructions (Immunohistochemistry reagents Kit, Bio
SB). Staining was developed in 1% diaminobenzidine (DAB) in
Buffer DAB solution for 1 min to 3 min and then quenched in PBS.
Slides were counterstained with hematoxylin for 20 s and covered
with a coverslip.
Statistical analysis
For all data comparison, the Student’s t-test was performed
using Microsoft excel. A p value of o0.05 was considered
statistically signiﬁcant.Acknowledgements
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